688677.SH
海泰新光
SSE · Healthcare · Medical - Instruments & Supplies · CN
CNY 84.25
−8.35%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 630.2M | 602.6M | 442.8M | 470.6M | 476.8M |
| Cost of Revenue | 218.7M | 207.0M | 157.2M | 170.7M | 170.0M |
| Gross Profit | 411.5M | 395.6M | 285.7M | 299.9M | 306.8M |
| Operating Expenses | |||||
| R&D Expense | 74.7M | 72.7M | 54.1M | 65.9M | 59.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 66.8M | 63.6M | 52.2M | 53.3M | 42.4M |
| Selling & Marketing Expense | 52.5M | 50.6M | 25.7M | 18.1M | 15.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 204.3M | 192.6M | 128.3M | 138.8M | 109.0M |
| Cost and Expenses | 423.0M | 399.6M | 285.4M | 309.5M | 279.0M |
| Operating Income (EBIT) | 190.9M | 190.1M | 152.9M | 161.0M | 206.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 191.5M | 190.8M | 152.5M | 160.2M | 205.5M |
| Income Tax Expense | 25.3M | 24.9M | 18.7M | 18.1M | 23.8M |
| Bottom Line | |||||
| Net Income | 171.3M | 170.7M | 135.3M | 145.7M | 182.6M |
| Earnings from Cont. Ops | 166.2M | 165.9M | 133.8M | 142.2M | 181.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 171.3M | 170.7M | 135.3M | 145.7M | 182.6M |
| Per Share | |||||
| Basic EPS | CN¥1.44 | CN¥1.44 | CN¥1.12 | CN¥1.20 | CN¥1.50 |
| Diluted EPS | CN¥1.44 | CN¥1.44 | CN¥1.12 | CN¥1.20 | CN¥1.50 |
| Revenue Per Share | CN¥5.34 | CN¥5.08 | CN¥3.66 | CN¥3.88 | CN¥3.92 |
| Shares | |||||
| Basic Shares Outstanding | 118.0M | 118.6M | 120.8M | 121.4M | 121.7M |
| Diluted Shares Outstanding | 118.0M | 118.6M | 120.8M | 121.4M | 121.7M |
| Profitability Metrics | |||||
| EBITDA | — | 225.0M | 179.8M | 183.8M | 220.2M |
| D&A | — | 34.9M | 26.8M | 22.8M | 13.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026